がん性腹膜炎（PC）- 市場洞察、疫学、市場予測 2028年
Peritoneal Carcinomatosis (PC) Market Insights, Epidemiology and Market Forecast - 2028
|がん性腹膜炎（PC）- 市場洞察、疫学、市場予測 2028年|
発行: DelveInsight Business Research LLP
ページ情報: 英文 116 Pages
DelveInsight's 'Peritoneal Carcinomatosis (PC) - Market Insights, Epidemiology and Market Forecast-202'8 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PCs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Peritoneal Carcinomatosis (PC) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2017-2028
Peritoenal Carcinomatosis (PC) is a rare type of cancer that develops with the spread of gastrointestinal or gynecologic cancers which cause tumors to grow in the peritoneum. Patients often fail to notice the problem until PC advances. This happens mostly because the disease does not cause unusual symptoms, especially in its early stages. These factors lead to a significant amount of underestimation of the exact patient pool. An improved understanding of the global burden of PC, could have a significant effect on an early intervention and treatment.
The DelveInsight Peritoneal Carcinomatosis (PC) market report gives the thorough understanding of the Peritoneal Carcinomatosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Peritoneal Carcinomatosis in the US, Europe and Japan.
The Peritoneal Carcinomatosis (PC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incidence of PC in Advanced Stage Cancers, Incidence of PC in Site Specific Cancers, Total Incidence of PC in Recurrent Cases, Incidence of PC by site-specific Recurrent Cases) scenario of Peritoneal Carcinomatosis (PC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to DelveInsight, the total number of Incident cases of Peritoneal Carcinomatosis (PC) in 7 MM was found to be 91,416 in the year 2017.
This segment of the Peritoneal Carcinomatosis report encloses the detailed analysis of marketed drugs and late stage (Phase-II and Phase-I) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Despite the progress being made and the active research currently underway in peritoneal carcinomatosis, it remains a highly lethal condition. Oncolytic virotherapy is an emerging treatment modality for cancers of various origins and specifications. Oncolytic viruses (OV) are designed to selectively infect and damage cancerous tissues by intracellular replication and subsequent oncolysis without causing harm to normal tissues. As with most other types of cancer, there is growing interest in the genomic profiling of peritoneal carcinomatosis to gain insight into the biology of this form of metastatic disease. It is hoped that understanding the genetic mutations that drive cancer progression within the peritoneum will help to identify more specific targets for treatment.
The Peritoneal Carcinomatosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of emerging therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Peritoneal Carcinomatosis in 7MM was found to be USD 974 Million in 2017, and is expected to increase during the course of the study period (2017-2028). The United States accounts for the largest market size of Peritoneal Carcinomatosis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Note: We understand the needs of the rapidly changing market and DelveInsight's is helping the client by providing the most up to date Report. It usually takes 24 Hours to deliver this kind of Report.